Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

THE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, reported positive data from a recently completed clinical trial and mechanistic study of LX4211, a dual inhibitor of the sodium glucose transporters 1 and 2 (SGLT1 and SGLT2).  The favorable safety profile and effects on multiple parameters of glycemic control and cardiovascular health in healthy normal subjects support the broad potential of LX4211 in the treatment of diabetes and associated metabolic conditions.

"Newly observed in this study were the effects of LX4211, in healthy volunteers, of decreasing postprandial glucose levels without hypoglycemia and substantially reducing triglycerides," said Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer.  "Notably, the magnitudes of the reductions in triglycerides were similar to current standard of care prescription and clinical-stage medicines. By contrast, reported results of SGLT2-selective compounds have demonstrated minimal or no reductions in postprandial glucose in healthy subjects and minimal or no triglyceride decreases in either healthy normal volunteers or patients with type 2 diabetes."

Results from the study demonstrated that the 400 mg solid oral dose of LX4211 compared to placebo significantly reduced mean changes from baseline in fasting plasma glucose (p=0.005) and post-prandial glucose levels (p<0.001) in parallel with meaningful mean increases from baseline in total and active GLP-1 (p=0.055 and p=0.003, respectively) as well as PYY (p<0.001).  GLP-1 is associated with improved glucose control and decreased food intake through reduction of appetite.  PYY is a gas
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  Zimmer Holdings, Inc. ... announced the future executive leadership team and organizational structure ... Biomet transaction.  Zimmer also announced that the combined organization ... will be named Zimmer Biomet, with the new brand ... the closing of the merger.  The future leadership team ...
(Date:10/30/2014)... NEW YORK , Oct. 30, 2014  The ... United States is growing steadily, thanks to ... years, as a result of the economic downturn, retail ... was a year of opportunities, as the number of ... market researcher,s report, Retail Clinics Market Overview and ...
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
Breaking Medicine Technology:Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3China Biologic to Report Third Quarter 2014 Financial Results 2
... REGN ) today announced that the Company ... agreement (Agreement) with Genentech, Inc., a member of the ... U.S. ophthalmic sales of EYLEA™ (aflibercept) Injection. ... relating to VEGF receptor proteins, known as the Davis-Smyth ...
... testing, the gold standard in hypothyroid diagnosis, may be ... article titled Hormone Replacement Therapy in the ... for the Future. Estrogen, Progesterone, Testosterone, and Thyroid Hormone ... independently written and published, is a broad study of ...
Cached Medicine Technology:Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection 2Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection 3Studies Show That TSH Is Unreliable in the Diagnosis of Hypothyroidism According to Article Contributed by Kent Holtorf, M.D. in Clinical Geriatrics 2
(Date:10/30/2014)... cancer care respects the fact that a patient,s ... requires treatment. Over a third of cancer patients ... of their conditions. And, increasingly, care providers are ... patients navigate mental health challenges. A University of ... journal Psycho-Oncology asks an important question: ...
(Date:10/29/2014)... The development of minimally and even non-invasive technologies is ... for instance, to carry out a range of operative ... scalpel, leaving only tiny scars as a result. Similar ... active agents to patients – instead of using injections ... be possible to supply them via a plaster which ...
(Date:10/29/2014)... certain prostate cancer medications are linked with an increased ... congestive heart failure or prior heart attacks. Published in ... and patients weigh the benefits and risks of the ... levels of male hormones in the body to prevent ... treatment for prostate cancer. Despite its anticancer effects, ADT ...
(Date:10/28/2014)... and outer body and organ surfaces in the human ... in the inner ear," said Moritz Gegg. Cilia – ... are precisely positioned on many of these epithelial cells. ... coordinated so precisely that for example mucus can be ... from sensory inner ear hair cells," added Heiko Lickert. ...
(Date:10/28/2014)... NY (October 27, 2014)—Although oral hormonal therapy is ... women with hormone receptor–positive tumors, about one-half of ... A study by Columbia University Medical Center (CUMC) ... aromatase inhibitors (the most common type of hormone ... brand-name counterparts, increased treatment adherence by 50 percent. ...
Breaking Medicine News(10 mins):Health News:Decades of research: Effectiveness of phone counseling for cancer patients still unknown 2Health News:Gentle caffeine boost for premature babies 2Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2Health News:New insights into the development of ciliopathies 2Health News:Generic medications boost adherence to breast cancer therapy 2Health News:Generic medications boost adherence to breast cancer therapy 3
... , MONDAY, Jan. 17 (HealthDay News) -- Patients at high ... detect the deadly skin cancer at an early stage, new ... some people from having a doctor examine their skin for ... Archives of Dermatology . People at high risk for ...
... HealthDay Reporter , MONDAY, Jan. 17 (HealthDay News) -- ... flares of multiple sclerosis (MS), but does not help ... guidelines say. Plasma exchange, or plasmapheresis, is also ... chronic inflammatory demyelinating polyneuropathy and it may be considered ...
... poor can prevent young children from reaching their full genetic potential ... University of Texas at Austin looked at 750 sets of twins ... and 2 years. During the tests the children were asked to ... placing three cubes in a cup, and matching pictures. At ...
... HealthDay Reporter , MONDAY, Jan. 17 (HealthDay News) -- ... called calcium channel blockers face an increased risk of ... shock if they take certain antibiotics, Canadian researchers warn. ... to patients taking calcium channel blockers, can increase the ...
... -- Among middle-school students, friendships can make the difference ... Students whose friends are socially active in positive ways ... badly get lower grades, according to the results of ... also staying away from deviant peers was associated with ...
... surgery remains significantly different when compared to the patient,s opposite ... a study that updated prior findings, researchers used X-rays providing ... relation to the shoulder blade, to compared motion in the ... tendon tears and no symptoms in their other shoulders. An ...
Cached Medicine News:Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 2Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 3Health News:Some Severe MS Flares Helped by Blood Filtering Treatment 2Health News:Some Severe MS Flares Helped by Blood Filtering Treatment 3Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 2Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 3Health News:Friends a Big Influence on Grades in Middle School: Study 2Health News:Henry Ford Hospital study: Shoulder function not fully restored after surgery 2
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The design of the large pediatric underbody blanket conveniently warms the large child or small adult patient while allowing full access for surgeons and staff....
Similar to Model 530, but just 37 inches long and with only one drape....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers. Polyethylene cover....
Medicine Products: